Live Analyst Rating Changes 8035 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Ryan Deschner
RJ
Ryan Deschner
Raymond James
Wall Street Analyst
★★★★☆
#380
on 13Foresight · ranked by our own returns
68%
Success Rate
+15.8%
Average Return
13 of 19 calls profitable · +7.3% vs benchmark
📈 Across the calls we could measure, roughly 68% of Ryan Deschner's ratings turned a profit when each position was held for 1 year — averaging +15.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

34 Buy 4 Hold 0 Sell
Ryan's Stock Coverage 16 ratings · 2026-07-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
ACOG
Alpha Cognition Inc
 Jul 10, 2026 BUY Strong Buy
+98.2% avg upside
4 analysts
$20.00
137.79% Upside
 ·
TVRD
Tvardi Therapeutics
 Jul 08, 2026 BUY Strong Buy
+452.6% avg upside
23 analysts
$10.00
204.81% Upside
 +0.0%
PRQR
ProQR
 Jun 26, 2026 BUY Strong Buy
+552.9% avg upside
18 analysts
$10.00
478.06% Upside
 ·
ACHV
Achieve Life Sciences
 Jun 26, 2026 BUY Strong Buy
+153.0% avg upside
13 analysts
$20.00
227.35% Upside
 +3.2%
VKTX
Viking Therapeutics
 Jun 24, 2026 BUY Strong Buy
+85.1% avg upside
31 analysts
 — +2.6%
VERA
Vera Therapeutics
 Jun 24, 2026 BUY Strong Buy
+69.4% avg upside
19 analysts
 — +5.8%
DNTH
Dianthus Therapeutics
 Jun 12, 2026 BUY Strong Buy
-8.0% avg upside
29 analysts
 — +18.9%
ADMA
ADMA Biologics
 Jun 10, 2026 BUY Strong Buy
+43.9% avg upside
15 analysts
$21.00
131.25% Upside
 +7.1%
LQDA
Liquidia Technologies
 Jun 04, 2026 BUY Strong Buy
-27.4% avg upside
15 analysts
 — +24.6%
IFRX
InflaRx
 May 13, 2026 BUY Buy
+345.1% avg upside
11 analysts
$9.00
339.02% Upside
 -5.6%
MIRM
Mirum Pharmaceuticals
 May 07, 2026 BUY Strong Buy
-4.0% avg upside
21 analysts
$165.00
35.10% Upside
 +25.0%
KRRO
Korro Bio
 Mar 13, 2026 BUY Strong Buy
+85.9% avg upside
19 analysts
$23.00
58.05% Upside
 +9.4%
SPRY
ARS Pharmaceuticals
 Jan 09, 2026 BUY Strong Buy
+170.5% avg upside
12 analysts
 — -39.7%
PVLA
Palvella Therapeutics
 Nov 19, 2025 BUY Strong Buy
+14.8% avg upside
27 analysts
$143.00
1.17% Downside
 +49.4%
TRVI
Trevi Therapeutics
 Aug 08, 2025 BUY Strong Buy
+13.2% avg upside
16 analysts
$27.00
51.37% Upside
 +154.0%
ARDX
Ardelyx
 Aug 05, 2025 BUY Strong Buy
+156.7% avg upside
21 analysts
$12.00
127.22% Upside
 +5.1%
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Ryan Deschner — Frequently Asked Questions
How accurate are Ryan Deschner's stock ratings?
Based on the calls 13Foresight could measure, about 68% of Ryan's ratings were profitable over a one-year hold, with an average return of +15.9% per rating, or +7.4% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Ryan ranked on 13Foresight?
Ryan Deschner is currently ranked #380 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Ryan cover?
Ryan most recently has ratings on ACOG, TVRD, PRQR, ACHV, VKTX, VERA, DNTH, ADMA, LQDA, IFRX, MIRM, KRRO and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.